Annovis Bio announced that Alzheimer’s, AD, phase II/III study of its lead compound buntanetap has exceeded full enrollment. “We are very pleased to share the news of the successful completion of enrollment for our phase II/III study of buntanetap in Alzheimer’s Disease,” said Annovis’ founder, president and CEO, Maria Maccecchini, Ph.D. “The number of enrolled patients exceeded our initial projections, revealing the Alzheimer’s community’s strong endorsement of our mission to develop a treatment targeting multiple neurotoxic proteins. This not only proves their support but also underscores their willingness to contribute to advancing this important cause.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANVS:
- Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
- Annovis Bio price target lowered to $30 from $40 at H.C. Wainwright
- Annovis Bio initiated with a Buy at Brookline
- Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Annovis Bio reports Q3 net loss of $14.7M vs. $6.4M last year